These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10893956)

  • 21. Ziagen (abacavir) approved: caution essential.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.
    de la Rosa R; Harris M; Uyeda L; Goodison K; Keown P; Montaner JS
    AIDS; 2004 Feb; 18(3):578-9. PubMed ID: 15090818
    [No Abstract]   [Full Text] [Related]  

  • 24. Preliminary report on 1592.
    AIDS Clin Care; 1997 Sep; 9(9):71. PubMed ID: 11364756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy.
    Tenorio AR; Irlanda IE; Narkiewicz E; Smith KY; Kessler HA; Sha BE
    AIDS; 2000 Jul; 14(10):1470-1. PubMed ID: 10930173
    [No Abstract]   [Full Text] [Related]  

  • 28. Hypersensitivity reactions reported with abacavir.
    AIDS Patient Care STDS; 1998 May; 12(5):405-6. PubMed ID: 11361980
    [No Abstract]   [Full Text] [Related]  

  • 29. A near-fatal hypersensitivity reaction to abacavir: case report and literature review.
    Shapiro M; Ward KM; Stern JJ
    AIDS Read; 2001 Apr; 11(4):222-6. PubMed ID: 11392679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.
    Phillips EJ; Sullivan JR; Knowles SR; Shear NH
    AIDS; 2002 Nov; 16(16):2223-5. PubMed ID: 12409746
    [No Abstract]   [Full Text] [Related]  

  • 31. Abacavir hypersensitivity reaction.
    Hewitt RG
    Clin Infect Dis; 2002 Apr; 34(8):1137-42. PubMed ID: 11915004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No rechallenge for abacavir.
    AIDS Patient Care STDS; 2004 Dec; 18(12):737. PubMed ID: 15669129
    [No Abstract]   [Full Text] [Related]  

  • 34. Kawasaki-like syndrome: abacavir hypersensitivity?
    Toerner JG; Cvetkovich T
    Clin Infect Dis; 2002 Jan; 34(1):131-3. PubMed ID: 11731962
    [No Abstract]   [Full Text] [Related]  

  • 35. Severe hypersensitivity reactions following reintroduction of abacavir.
    AIDS Read; 2000 Sep; 10(9):525. PubMed ID: 11019447
    [No Abstract]   [Full Text] [Related]  

  • 36. [Acceptance of antiretroviral therapy. HIV-infected patients assess convenient triple combination].
    MMW Fortschr Med; 2001 Sep; 143(35-36):56. PubMed ID: 11584535
    [No Abstract]   [Full Text] [Related]  

  • 37. New abacavir data open door to a better treatment paradigm.
    AIDS Alert; 1998 Aug; 13(8):85-7. PubMed ID: 11365647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
    McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
    Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review.
    Rizzardini G; Capetti A
    Med Sci Monit; 2006 Dec; 12(12):RA269-276. PubMed ID: 17136016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scientists find some genes a bad omen for anti-HIV drug.
    Stephenson J
    JAMA; 2002 Apr; 287(13):1637. PubMed ID: 11926874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.